Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fava

Showing results (281-290 of 332) with videos related to

Pageof 34
Sort By:
Plos Genetics|August 10, 2017
Deciphering the genetic control of gene expression following Mycobacterium leprae antigen stimulationJérémy Manry, Yohann Nédélec, Vinicius M Fava, et al.
Frontiers in Immunology|May 8, 2026
Continuous antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophagesVinicius M Fava, Monica Dallmann-Sauer, Marianna Orlova, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 8, 2007
A detailed examination of cytokine abnormalities in Major Depressive DisorderN M Simon, K McNamara, C W Chow, et al.
The American Journal of Psychiatry|November 1, 1992
Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administrationP F Renshaw, A R Guimaraes, M Fava, et al.
Journal of Affective Disorders|November 4, 2017
Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1]D Mischoulon, L Hylek, A S Yeung, et al.
Plos Neglected Tropical Diseases|December 8, 2021
Deep resequencing identifies candidate functional genes in leprosy GWAS lociVinicius M Fava, Monica Dallmann-Sauer, Marianna Orlova, et al.
The American Journal of Psychiatry|September 12, 1998
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatmentF W Reimherr, J D Amsterdam, F M Quitkin, et al.
Molecular Psychiatry|January 11, 2019
A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorderG I Papakostas, K Johe, H Hand, et al.
Psychological Medicine|June 5, 2009
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) reportA F Leuchter, M M Husain, I A Cook, et al.
Journal of Clinical Psychopharmacology|August 10, 1999
Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorderM Fava, J F Rosenbaum, A R Kolsky, et al.
Pageof 34

Showing results (281-290 of 332) with videos related to

Sort By:
Pageof 34
Plos Genetics|August 10, 2017
Deciphering the genetic control of gene expression following Mycobacterium leprae antigen stimulationJérémy Manry, Yohann Nédélec, Vinicius M Fava, et al.
Frontiers in Immunology|May 8, 2026
Continuous antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophagesVinicius M Fava, Monica Dallmann-Sauer, Marianna Orlova, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 8, 2007
A detailed examination of cytokine abnormalities in Major Depressive DisorderN M Simon, K McNamara, C W Chow, et al.
The American Journal of Psychiatry|November 1, 1992
Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administrationP F Renshaw, A R Guimaraes, M Fava, et al.
Journal of Affective Disorders|November 4, 2017
Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1]D Mischoulon, L Hylek, A S Yeung, et al.
Plos Neglected Tropical Diseases|December 8, 2021
Deep resequencing identifies candidate functional genes in leprosy GWAS lociVinicius M Fava, Monica Dallmann-Sauer, Marianna Orlova, et al.
The American Journal of Psychiatry|September 12, 1998
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatmentF W Reimherr, J D Amsterdam, F M Quitkin, et al.
Molecular Psychiatry|January 11, 2019
A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorderG I Papakostas, K Johe, H Hand, et al.
Psychological Medicine|June 5, 2009
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) reportA F Leuchter, M M Husain, I A Cook, et al.
Journal of Clinical Psychopharmacology|August 10, 1999
Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorderM Fava, J F Rosenbaum, A R Kolsky, et al.
Pageof 34